AGA’s first-ever living guideline categorizes the 12 available treatments for patients with moderate-to-severe ulcerative colitis based on efficacy. This approach aims to streamline your decision-making, with a new recommendation to prioritize advanced therapies and/or immunomodulators rather than using a step-up approach following 5-aminosalicylates (5-ASA) failure.
